Zichang Xu
-
- Monoclonal and Polyclonal Antibodies Research 7
-
- SARS-CoV-2 and COVID-19 Research 3
-
- vaccines and immunoinformatics approaches 9
- Glycosylation and Glycoproteins Research 3
- Microbial Metabolic Engineering and Bioproduction 2
- RNA and protein synthesis mechanisms 2
- Enzyme Catalysis and Immobilization 2
-
- T-cell and B-cell Immunology 3
- Co-authors
- Daron M. StandleyShunsuke TeraguchiAna DavilaTeeradaj RacharakYizhi PanLe-Minh NguyenJianhua MaSongling Li
In The Last Decade
Zichang Xu
14 papers receiving 264 citations
Hit Papers
Peers
Comparison fields: 5 of 68
- Radiology, Nuclear Medicine and Imaging 91
- Neurology 26
- Computer Vision and Pattern Recognition 49
- Infectious Diseases 40
- Molecular Biology 127
Countries citing papers authored by Zichang Xu
This map shows the geographic impact of Zichang Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zichang Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zichang Xu more than expected).
Fields of papers citing papers by Zichang Xu
This network shows the impact of papers produced by Zichang Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zichang Xu. The network helps show where Zichang Xu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Zichang Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | DA-TransUNet: integrating spatial and channel dual attention with transformer U-net for medical image segmentationbreakdown → | 2024 | 88 |
| 3 | 2023 | 3 | |
| 4 | 2022 | 21 | |
| 5 | 2022 | 1 | |
| 6 | 2022 | 4 | |
| 7 | 2022 | 9 | |
| 8 | 2022 | 28 | |
| 9 | 2022 | 2 | |
| 10 | 2020 | 24 | |
| 11 | 2020 | 27 | |
| 12 | 2019 | 16 | |
| 13 | 2019 | 19 | |
| 14 | 2019 | 14 | |
| 15 | 2019 | 10 |
About Zichang Xu
Zichang Xu is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Molecular Biology, having authored 15 papers that have together received 266 indexed citations. Recurring topics across this work include vaccines and immunoinformatics approaches (9 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), SARS-CoV-2 and COVID-19 Research (3 papers), Glycosylation and Glycoproteins Research (3 papers), T-cell and B-cell Immunology (3 papers), Microbial Metabolic Engineering and Bioproduction (2 papers), RNA and protein synthesis mechanisms (2 papers) and Enzyme Catalysis and Immobilization (2 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (91 citations), Neurology (26 citations) and Computer Vision and Pattern Recognition (49 citations). Zichang Xu has collaborated with scholars based in Japan, Mexico and China. Frequent co-authors include Daron M. Standley, Shunsuke Teraguchi, Ana Davila, Teeradaj Racharak, Yizhi Pan, Le-Minh Nguyen, Jianhua Ma, Songling Li, John Rozewicki and Floris J. van Eerden. Their work appears in journals such as Computational and Structural Biotechnology Journal, Applied Microbiology and Biotechnology, Frontiers in Bioengineering and Biotechnology, ChemBioChem and Briefings in Bioinformatics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.